On July 15, 2019, the seventeenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On June 5, 2019, the fifteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On May 1, 2019, the thirteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On March 6, 2019, the twelfth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On February 20, 2019, the fourteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On October 17, 2018, the ninth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On August 27, 2018, the eighth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On August 24, 2018, the seventh participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On November 9, 2017, the Institutional Review Board approved the study protocol for the effect of MDMA on startle testing in healthy volunteers. This MAPS-sponsored study will be conducted by Principal …
On March, 15, 2018, the first participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
On January 3, 2017, the Institutional Review Board (IRB) at Emory University approved the first protocol amendment for our upcoming Phase 1 study onthe effect of MDMA on startle testing in healthy volunteers. …
On November 30, 2016, the FDA cleared the upcoming MAPS-sponsored Phase 1 study on the effect of MDMA on startle testing in healthy volunteers. Principal Investigator Barbara Rothbaum, Ph.D., a leading …
